Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Clin Gastroenterol Hepatol. 2022 May;20(5):e1022-e1039. doi: 10.1016/j.cgh.2021.06.026. Epub 2021 Jun 30.
BACKGROUND & AIMS: In this nationwide population-based study, we investigated the risk of vertebral and hip fractures in patients with inflammatory bowel disease (IBD).
Using data from the Korean National Health Insurance claims database gathered between 2007 and 2016, we calculated the incidence rate ratios (IRRs) of vertebral and hip fractures in patients with newly diagnosed IBD (n = 18,228; 64.1% male, 65.9% ulcerative colitis) compared with an age- and sex-matched control population (matching ratio, 1:10; n = 186,871).
During a median follow-up period of 4.5 years, the incidence rate and IRR of vertebral and hip fractures in patients with IBD were 2.88 per 1000 person-years and 1.24 (95% CI, 1.08-1.42), respectively. The cumulative risk of vertebral and hip fractures in IBD patients was 0.6%, 1.4%, and 1.9% at 2, 5, and 7 years after diagnosis, respectively, and this risk of fracture in IBD patients was higher than that in matched controls (P = .002). The use of corticosteroids further increased the risk of fractures in IBD patients (IRR, 1.37; 95% CI, 1.13-1.65) compared with matched controls. The risk of fractures was significantly higher in patients with Crohn's disease (CD) (IRR, 1.56; 95% CI, 1.19-2.04) than in matched controls, and this risk remained higher in patients with CD without corticosteroid exposure (IRR, 1.62; 95% CI, 1.12-2.34). The risk of fracture increased with age and was particularly high in females and in those with comorbidities.
The risk of fractures was significantly high in newly diagnosed IBD patients, especially in those with CD regardless of corticosteroid exposure.
本项全国性基于人群的研究旨在调查炎症性肠病(IBD)患者发生椎体和髋部骨折的风险。
利用 2007 年至 2016 年期间韩国国家健康保险索赔数据库的数据,我们计算了新诊断为 IBD(n=18228 例;64.1%为男性,65.9%为溃疡性结肠炎)患者与年龄和性别相匹配的对照人群(匹配率为 1:10;n=186871 例)中椎体和髋部骨折的发病率比值(IRR)。
在中位随访 4.5 年期间,IBD 患者椎体和髋部骨折的发病率和 IRR 分别为 2.88/1000 人年和 1.24(95%CI,1.08-1.42)。IBD 患者在诊断后 2、5 和 7 年时椎体和髋部骨折的累积风险分别为 0.6%、1.4%和 1.9%,且 IBD 患者骨折风险高于匹配对照者(P=0.002)。与匹配对照者相比,IBD 患者使用皮质类固醇会进一步增加骨折风险(IRR,1.37;95%CI,1.13-1.65)。与匹配对照者相比,克罗恩病(CD)患者的骨折风险更高(IRR,1.56;95%CI,1.19-2.04),且在未使用皮质类固醇的 CD 患者中这种风险仍然更高(IRR,1.62;95%CI,1.12-2.34)。骨折风险随年龄增长而增加,且女性和合并症患者的风险尤其高。
新诊断为 IBD 的患者,尤其是无论是否使用皮质类固醇的 CD 患者,其骨折风险显著升高。